Improvement of Urinary Dysfunction After Kidney Transplantation by Administration of the Antimuscarinic Agent-Prospective Randomized Controlled Study.
Tsunoyama K, Ishida H, et al.Transplantation 93(6):597-602, 2012.
Aims
To evaluate the efficacy of an antimuscarinic agent in improving urinary dysfunction in kidney transplantation.
Interventions
Oral 5mg solifenacin per day for 6 weeks versus no treatment of any antimuscarinic agent.
Participants
33 renal transplant patients with diagnosis of dysfunctional bladder.
Outcomes
Video water cystometric parameters were daily urine volume, the volume at first sensation, the maximum cystometric capacity, the bladder compliance, the prevalence of lower urinary tract symptoms after transplant, and quality of life assessment including general health perception, incontinence impact, social limitations, personal relationships and sleep/energy.
Follow-up
6 weeks
CET Conclusions
This is an interesting study in which patients with a small capacity bladder who received a kidney transplant were randomised to be treated with an antimuscarinic agent (solifenacin) or not. Bladder function and quality of life parameters were measured and there was a very major improvement in those patients who had received the antimuscarinic agent.
Data analysis
Per protocol analysis
Trial registration
Not reported